May 15, 2024 8:45am EDT Inhibikase Therapeutics Announces Request for Withdrawal of S-1 Registration Statement
May 09, 2024 8:00am EDT Inhibikase Therapeutics Announces Final Pre-IND Meeting Outcomes for IkT-001Pro as a Treatment for Pulmonary Arterial Hypertension
Apr 18, 2024 4:30pm EDT Inhibikase Therapeutics Issues Letter to Shareholders and Provides Update on Development Programs
Apr 03, 2024 8:05am EDT Inhibikase Therapeutics Announces Pre-IND Meeting with the FDA for IkT-001Pro in Pulmonary Arterial Hypertension
Mar 27, 2024 4:15pm EDT Inhibikase Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Activity
Mar 07, 2024 8:30am EST Inhibikase Therapeutics to Provide Trial Update for Risvodetinib at the 2024 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders
Feb 28, 2024 4:05pm EST Inhibikase Therapeutics Announces Full Outcomes of its Pre-NDA Meeting with the FDA for IkT-001Pro
Feb 07, 2024 7:55am EST Inhibikase Therapeutics Announces Preliminary Outcomes of its Pre-NDA Meeting with the FDA on the Pathway for Approval for IkT-001Pro in Blood and Gastrointestinal Cancers
Jan 29, 2024 9:05am EST Inhibikase Therapeutics Announces Publication Highlighting Results from its Phase 1 Studies with Risvodetinib
Jan 16, 2024 4:05pm EST Inhibikase Therapeutics Announces Planned Retirement of Chief Financial Officer Joseph Frattaroli